CJC-1295 (No DAC) vs IGF-1 LR3
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29), engineered for a long duration of action. The form most people mean by CJC-1295 includes a Drug Affinity Complex (DAC) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising GH and IGF-I for days from a single injection. It was developed by ConjuChem, reached Phase II trials and was abandoned; it is not an approved drug and is sold only as a research chemical. A version without DAC (Modified GRF 1-29) acts for only about 30 minutes.
Also: Long R3 IGF-1, LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. It is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. Everything below the mechanism section is preclinical work, laboratory use, or community reporting.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- CJC-1295 (No DAC) has stronger research evidence (Human Trials) compared to IGF-1 LR3 (Preclinical).
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | IGF-1 LR3 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. | Natural IGF-1 is almost entirely bound up by IGF binding proteins in circulation, which controls how much is active and gives it a half-life measured in minutes. LR3 makes two changes: an arginine substitution at position 3, and a 13-amino-acid extension on the N-terminus. Together these dramatically reduce binding-protein affinity, so far more of the molecule stays free and active, extending the functional half-life to something on the order of a day rather than minutes. Once free, it activates the IGF-1 receptor, driving protein synthesis, satellite cell activation and cell proliferation in muscle. That same lack of binding-protein regulation is the reason for caution: binding proteins are a control mechanism, and removing the control is the point of the drug and also its main risk. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 20-50 mcg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection. Because of the hypoglycemia risk, timing relative to carbohydrate intake is the main practical consideration reported. |
| Typical Duration | 8-12 weeks | Community cycles are typically reported as 4-6 weeks, on the reasoning that receptor downregulation follows longer use |
| Best Time to Take | Before bed | With or near a carbohydrate-containing meal |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. Beyond pharmacokinetics and hormone levels, there are no large long-term human trials demonstrating clinical benefits like fat loss or muscle gain, so those claims are not established by published trials. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. Bottom line: the GH and IGF-I-raising effect and long half-life are well supported, while real-world efficacy and long-term safety are not. | IGF-1 LR3 was developed as a cell culture reagent, and that remains its principal legitimate use: it is sold to laboratories to promote cell growth in bioreactors. There are no published randomized human trials of IGF-1 LR3 for muscle growth, body composition or performance. The animal and in vitro work does show what you would expect, increased protein synthesis and muscle cell proliferation, and there is a genuine human literature on recombinant IGF-1 (mecasermin) for severe IGF-1 deficiency, but mecasermin is a different molecule with different pharmacokinetics and its trial data should not be read across. The two consistent safety themes in the underlying biology are hypoglycemia, because IGF-1 has meaningful cross-reactivity with the insulin receptor, and the theoretical concern that chronically elevated IGF-1 signalling promotes growth of tissue you did not intend to grow, including existing tumors. |
Frequently Asked Questions: CJC-1295 (No DAC) vs IGF-1 LR3
What is the difference between CJC-1295 (No DAC) and IGF-1 LR3?
CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29), engineered for a long duration of action. the form most people mean by cjc-1295 includes a drug affinity complex (dac) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising gh and igf-i for days from a single injection. it was developed by conjuchem, reached phase ii trials and was abandoned; it is not an approved drug and is sold only as a research chemical. a version without dac (modified grf 1-29) acts for only about 30 minutes. IGF-1 LR3 is a growth hormone peptide that igf-1 lr3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. it is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. everything below the mechanism section is preclinical work, laboratory use, or community reporting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or IGF-1 LR3?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while IGF-1 LR3 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and IGF-1 LR3 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and IGF-1 LR3 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.